Literature DB >> 23296697

Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.

Meng Ling Moi1, Tomohiko Takasaki, Masayuki Saijo, Ichiro Kurane.   

Abstract

BACKGROUND: Dengue virus (DENV) infection-enhancing activity of pre-existing antibody has been suggested to be one of the factors responsible for the pathogenesis of the severe form of DENV infection, dengue haemorrhagic fever. Although studies of infection-enhancement activity using diluted serum sera are informative, infection-enhancement activity determined using undiluted sera may better reflect in vivo conditions.
METHODS: We determined whether serum samples collected from dengue patients possessed the ability to enhance DENV infection without dilution using FcγR-expressing cells.
RESULTS: Serum samples obtained at the early phase of secondary infection enhanced DENV infection without dilution. In contrast, sera obtained at the late stage of secondary infection demonstrated low levels or absence of infection-enhancing activity.
CONCLUSION: The results indicate that human sera obtained from patients with secondary infection possess the ability to enhance DENV infection without dilution, and suggest that antibody-dependent enhancement may occur in vivo during secondary DENV infection to infecting DENV serotypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296697     DOI: 10.1093/trstmh/trs007

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  13 in total

Review 1.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

2.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 3.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

4.  Formation of infectious dengue virus-antibody immune complex in vivo in marmosets (Callithrix jacchus) after passive transfer of anti-dengue virus monoclonal antibodies and infection with dengue virus.

Authors:  Meng Ling Moi; Yasushi Ami; Kenji Shirai; Chang-Kweng Lim; Yuriko Suzaki; Yuka Saito; Kazutaka Kitaura; Masayuki Saijo; Ryuji Suzuki; Ichiro Kurane; Tomohiko Takasaki
Journal:  Am J Trop Med Hyg       Date:  2014-12-29       Impact factor: 2.345

5.  Dengue in Florida (USA).

Authors:  Jorge R Rey
Journal:  Insects       Date:  2014-12-16       Impact factor: 2.769

Review 6.  Human antibody response to dengue virus: implications for dengue vaccine design.

Authors:  Meng Ling Moi; Tomohiko Takasaki; Ichiro Kurane
Journal:  Trop Med Health       Date:  2016-03-14

Review 7.  The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response.

Authors:  Jacky Flipse; Jolanda M Smit
Journal:  PLoS Negl Trop Dis       Date:  2015-06-11

8.  Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.

Authors:  Panjaporn Chaichana; Tamaki Okabayashi; Orapim Puiprom; Mikiko Sasayama; Tadahiro Sasaki; Akifumi Yamashita; Pongrama Ramasoota; Takeshi Kurosu; Kazuyoshi Ikuta
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

9.  First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies.

Authors:  Jowin Kai Wei Ng; Summer Lixin Zhang; Hwee Cheng Tan; Benedict Yan; Julia Maria Martinez; Wei Yu Tan; Jian Hang Lam; Grace Kai Xin Tan; Eng Eong Ooi; Sylvie Alonso
Journal:  PLoS Pathog       Date:  2014-04-03       Impact factor: 6.823

10.  Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses.

Authors:  Jacky Flipse; Mayra A Diosa-Toro; Tabitha E Hoornweg; Denise P I van de Pol; Silvio Urcuqui-Inchima; Jolanda M Smit
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.